Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1/Phase 2
cAMeLot-1 trial: what clinicians have said so far
A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)
- NCT04811560 ↗
- Recruiting
- Janssen Research & Development, LLC
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on cAMeLot-1 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on cAMeLot-1 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase 1/2, First-in-Human Study of the Menin-KMT2A (MLL1) Inhibitor Bleximenib in Participants With Acute Leukemia (cAMeLot-1)
- Phase
- Phase 1/Phase 2
- Status
- Recruiting
- Conditions
- Acute Leukemia
- Interventions
- Bleximenib
- Arms
- Bleximenib · Experimental
- Enrollment
- 420 (estimated)
- Primary outcomes
- Phase 1: Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability
- Phase 1: Number of Participants with AEs by Severity
- Phase 1: Part 1: Percentage of Participants with Dose-Limiting Toxicity (DLT)
- Phase 2: Rate of Complete Remission or Complete Remission with Partial Hematologic Recovery (CR/CRh)
- Sponsor
- Janssen Research & Development, LLC
- Start
- May 19, 2021
- Primary completion
- Dec 29, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT04811560 · updated Nov 4, 2026
Publications
linked from the registry- Kwon MC, Thuring JW, Querolle O, Dai X, Verhulst T, Pande V, Marien A, Goffin D, Wenge DV, Yue H, Cutler JA, Jin C, Perner F, Hogeling SM, Shaffer PL, Jacobs F, Vinken P, Cai W, Keersmaekers V, Eyassu F, Bhogal B, Verstraeten K, El Ashkar S, Perry JA, Jayaguru P, Barreyro L, Kuchnio A, Darville N, Krosky D, Urbanietz G, Verbist B, Edwards JP, Cowley GS, Kirkpatrick R, Steele R, Ferrante L, Guttke C, Daskalakis N, Pietsch EC, Wilson DM, Attar R, Elsayed Y, Fischer ES, Schuringa JJ, Armstrong SA, Packman K, Philippar U. Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemias. Blood. 2024 Sep 12;144(11):1206-1220. doi: 10.1182/blood.2023022480. PubMed 38905635